DNA vs. VCEL, KYMR, RXRX, SANA, CGON, NMRA, TWST, BEAM, DNLI, and FUSN
Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Vericel (VCEL), Kymera Therapeutics (KYMR), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), CG Oncology (CGON), Neumora Therapeutics (NMRA), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "biological products, except diagnostic" industry.
Ginkgo Bioworks (NYSE:DNA) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.
Ginkgo Bioworks presently has a consensus price target of $2.20, indicating a potential upside of 89.66%. Vericel has a consensus price target of $46.40, indicating a potential downside of 10.80%. Given Ginkgo Bioworks' higher probable upside, equities analysts plainly believe Ginkgo Bioworks is more favorable than Vericel.
Vericel received 312 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 62.38% of users gave Vericel an outperform vote while only 51.11% of users gave Ginkgo Bioworks an outperform vote.
In the previous week, Ginkgo Bioworks had 1 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Ginkgo Bioworks and 6 mentions for Vericel. Vericel's average media sentiment score of 0.53 beat Ginkgo Bioworks' score of 0.26 indicating that Vericel is being referred to more favorably in the news media.
Ginkgo Bioworks has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.
Vericel has a net margin of -1.61% compared to Ginkgo Bioworks' net margin of -355.08%. Vericel's return on equity of -1.55% beat Ginkgo Bioworks' return on equity.
78.6% of Ginkgo Bioworks shares are owned by institutional investors. 15.1% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vericel has lower revenue, but higher earnings than Ginkgo Bioworks. Vericel is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
Summary
Vericel beats Ginkgo Bioworks on 12 of the 18 factors compared between the two stocks.
Get Ginkgo Bioworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ginkgo Bioworks Competitors List
Related Companies and Tools